Coya Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $98.52M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | $200.00K | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | $300.00K | $-0.32 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 16, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | $3.60M | $-0.13 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | $200.00K | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | $257.88K | $-0.44 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 18, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 19, 2024 | Before market open | – | – | – |
Press releases
Announcements Coya Therapeutics filed with the SEC
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Results of operations · Other events · EX-99.1 to Form 8-K
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Coya Therapeutics Announces $11.1 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Coya Therapeutics Announces Proposed Public Offering of Common Stock
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Coya Therapeutics Announces $10.0 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1 st , 2024
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Coya Therapeutics Announces $5 Million Strategic
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. and Dr. Reddys Laboratories enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Coya Therapeutics Announces $26.5 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, joins Coyas Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
Regulation FD disclosure · EX-99.1 to Form 8-K
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
C. Masdeu , Stanley H. Appel 1 Stanley H. Appel Department of Neurology, Houston Methodist Research Institute, Houston, Texas, USA; 2 CSD Biostatistics, Inc., Oro Valley, Arizona, USA 3 Global R&D Partners, LLC, San Diego, California, USA; 4
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
Results of operations · EX-99 to Form 8-K
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results
Results of operations · EX-99 to Form 8-K
Stanley H. Appel, MD Jason Thonhoff,
Regulation FD disclosure · EX-99.1 to Form 8-K